

## Indoco declares Q1FY19 results

**Mumbai, August 13, 2018:** Indoco Remedies posted revenues of ₹ 212.5 crores during the first quarter of FY 2018-19, as against ₹ 204.2 crores, for the same quarter last year. The Company posted a loss of ₹ 12.0 crores as against loss of ₹ 20.8 crores, for the same quarter last year.

**Commenting on the 1<sup>st</sup> quarter results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said,** “Post GST transition and change in the business environment, the Indian Business registered good growth. Though International Business suffered on account of regulatory issues, we are confident that the same will be dealt with expeditiously”.

For the quarter ended June’18, the financials are as under:

(₹ in Crores)

Particulars	Apr’18-Jun’18	Apr’17-Jun’17
<b>Net Revenue</b>	212.5	204.2
<b>EBIDTA</b>	11.6	1.3
<b>Operating Profit</b>	0.9	(8.1)
<b>Profit / (Loss) After Tax</b>	(12.0)	(21.7)
<b>EPS (Face value ₹ 2/-) (Not annualized)</b>	(1.30)	(2.36)

### **About Indoco Remedies Limited:**

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 161 million Company, employs over 5500 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, MCC-South Africa, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from around

3,10,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Tuspel Plus, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit [www.indoco.com](http://www.indoco.com)

**For Media Inquiries Please Contact:**

**Vilas V. Nagare**

Mobile: 9820215745

E-mail: [vilasn@indoco.com](mailto:vilasn@indoco.com) / [corpcom@indoco.com](mailto:corpcom@indoco.com)